Hsbc Holdings PLC Sells 31,577 Shares of Roivant Sciences Ltd. $ROIV

Hsbc Holdings PLC cut its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 76.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,720 shares of the company’s stock after selling 31,577 shares during the period. Hsbc Holdings PLC’s holdings in Roivant Sciences were worth $273,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ROIV. UBS Group AG grew its holdings in Roivant Sciences by 570.0% during the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after buying an additional 15,645,836 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Roivant Sciences by 31.7% in the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after buying an additional 14,036,696 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Roivant Sciences by 365.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock worth $238,323,000 after buying an additional 8,621,567 shares in the last quarter. Norges Bank bought a new position in shares of Roivant Sciences during the fourth quarter worth $112,750,000. Finally, Jefferies Financial Group Inc. bought a new position in shares of Roivant Sciences during the fourth quarter worth $76,272,000. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Stock Performance

ROIV opened at $33.91 on Monday. The firm has a market cap of $24.39 billion, a P/E ratio of -56.52 and a beta of 1.12. Roivant Sciences Ltd. has a 12 month low of $10.90 and a 12 month high of $37.00. The stock has a 50-day moving average of $32.63 and a 200 day moving average of $29.10.

Analysts Set New Price Targets

Several research firms recently weighed in on ROIV. Bank of America reaffirmed a “neutral” rating on shares of Roivant Sciences in a research note on Friday. TD Cowen increased their price objective on shares of Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Citigroup increased their price objective on shares of Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Leerink Partners set a $42.00 price objective on Roivant Sciences in a research report on Thursday, May 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $34.00 target price on shares of Roivant Sciences in a report on Thursday, May 21st. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.59.

Insider Buying and Selling at Roivant Sciences

In other news, Director Daniel Allen Gold sold 12,380 shares of Roivant Sciences stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.28, for a total value of $436,766.40. Following the completion of the transaction, the director owned 13,689,166 shares in the company, valued at approximately $482,953,776.48. The trade was a 0.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $34.95, for a total value of $6,990,000.00. Following the transaction, the chief executive officer directly owned 1,613,063 shares in the company, valued at approximately $56,376,551.85. This represents a 11.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,055,913 shares of company stock worth $69,639,633 over the last ninety days. Company insiders own 8.80% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.